Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lanthanum carbonate

Drug Profile

Lanthanum carbonate

Alternative Names: Bay 771931; Fosrenol; Foznol; Lambda; SPD405

Latest Information Update: 11 Apr 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genzyme Corporation
  • Developer Bayer Yakuhin; Shire; Takeda
  • Class Hyperphosphataemia therapies; Lanthanoid series elements; Small molecules
  • Mechanism of Action Phosphate binding modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hyperphosphataemia

Most Recent Events

  • 08 Jan 2019 Shire has been acquired and merged into Takeda
  • 16 Nov 2018 Shire completes a phase II trial in Hyperphosphatemiain Argentina, Chile, Czech Republic, Germany, Hungary, Poland, Romania, Russia and Turkey (NCT01696279)
  • 31 Jan 2018 Lanthanum carbonate is still in phase II trials for Hyperphosphataemia (In adolescents, In children, In infants, Late-stage disease) in Argentina, Bulgaria, Chile, Czech Republic, Germany, Hungary, Poland, Romania, Russia, South Africa, and Turkey (NCT01696279)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top